Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Atomera, Inc. (ATOM)
NASDAQInformation TechnologySemiconductorsSnapshot 2026-11-04
$2.60-8.92%
Close 2026-11-05 · 1-day change
NASDAQInformation TechnologySemiconductorsSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for ATOM yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Reduce net losses and improve financial performance | Management aims to improve financial results despite recent losses of $6.07M in Q1 2026. | Broken | net loss worsens beyond -$6.07M in any quarter through 2026-Q4 | Net income: $-6.006M FY2026-Q3; GAAP. Published target: net loss less negative than -$4.43M by Q4 2026. The stored target says 2026-Q4; this source reports FY2026-Q3. Fiscal/calendar alignment needs review. Oct 30, 2026-6,006,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is speculative growth, not an established compounder: the business is loss-making, recent performance is weak, and risk is high. The long-term thesis is in a watch state, as reported progress has not yet turned into steady commercial revenue.
ATOM trades at a substantial premium to peers, while the valuation model has low confidence and points to optionality as the main driver. The expectations gap is elevated, but the evidence does not support assuming that customer interest will become meaningful revenue soon; the priced-in fragility assessment is low and tagged unjustified.
Near term, the run of three earnings misses and the latest quarter’s zero reported revenue leave execution under pressure, despite company momentum improving from its prior reading. Management continues to focus on MST adoption, GaN-on-silicon RF applications, and licensing and engineering services, but commercialization evidence remains limited.
Over the next few quarters, the key test is whether customer engagement and the IQE partnership lead to recurring revenue from MST licensing, engineering services, or RF products. A Fed rate-cutting cycle and stabilization among major technology companies could support the sector, while materially slower GDP growth would be a headwind.
Over a 1 to 3 year view, the thesis depends on ATOM turning promising customer activity into repeatable revenue; until then, the premium valuation and weak financial evidence leave the setup fragile. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Manage and reduce operating expenses | A supporting condition in Atomera, Inc.'s published investment case. The stated target is operating loss less negative than -$4.61M by Q4 2026. | Broken | operating loss worsens beyond -$6.32M in any quarter through 2026-Q4 | Operating income: $-6.328M FY2026-Q3; GAAP. Published target: operating loss less negative than -$4.61M by Q4 2026. The stored target says 2026-Q4; this source reports FY2026-Q3. Fiscal/calendar alignment needs review. Oct 30, 2026-6,328,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 3 of 3 supplied quarters. Management reported: “Financial Results The Company incurred a net loss of ($6.0) million, or ($0.15) per basic and diluted share in the third quarter of 2026, compared to a net loss of ($5.6) million, or ($0.17) per basic and diluted share, for the third quarter of 2025.” “Financial Results The Company incurred a net loss of ($6.3) million, or ($0.17) per basic and diluted share in the second quarter of 2026, compared to a net loss of ($5.0) million, or ($0.17) per basic and diluted share, for the second quarter of 2025.” Net income was $-6.006 million in 2026-Q3. Delivery assessment Nov 4, 2026 |
Increase revenue through MST adoption and strategic initiatives | Atomera is making progress with MST adoption by GAA manufacturers, which could boost revenue. | Intact | quarterly revenue falls below $11,000 in any quarter through 2026-Q4 | Revenue: $0 FY2026-Q3; GAAP. Published target: >= $50,000 quarterly revenue by Q4 2026. The stored target says 2026-Q4; this source reports FY2026-Q3. Fiscal/calendar alignment needs review. Oct 30, 20260 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.40 → $-0.44 · observed estimates
$0.00B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-07-25 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-07-26 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-07-27 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-07-28 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-07-29 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-07-30 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-07-31 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-08-01 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-08-02 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-08-03 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-08-04 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-08-05 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-08-06 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-08-07 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-08-08 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-08-09 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-08-10 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-08-11 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-08-12 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-08-13 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-08-14 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-08-15 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-08-16 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-08-17 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-08-18 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-08-19 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-08-20 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-08-21 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-08-22 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-08-23 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-08-24 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-08-25 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-08-26 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-08-27 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-08-28 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-08-29 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-08-30 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-08-31 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-09-01 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-09-02 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-09-03 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-09-04 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-09-05 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-09-06 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-09-07 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-09-08 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-09-09 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-09-10 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-09-11 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-09-12 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-09-13 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-09-14 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-09-15 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-09-16 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-09-17 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-09-18 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-09-19 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-09-20 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-09-21 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-09-22 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-09-23 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-09-24 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-09-25 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-09-26 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-09-27 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-09-28 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-09-29 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-09-30 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-10-01 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-10-02 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-10-03 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-10-04 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-10-05 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-10-06 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-10-07 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-10-08 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-10-09 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-10-10 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-10-11 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-10-12 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-10-13 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-10-14 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-10-15 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-10-16 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-10-17 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-10-18 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-10-19 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-10-20 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-10-21 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-10-22 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-10-23 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-10-24 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-10-25 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-10-26 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-10-27 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-10-28 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-10-29 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-10-30 | $-0.40 | $1,000,000 | 1 / 1 |
| 2026-10-31 | $-0.44 | $600,000 | 1 / 1 |
| 2026-11-01 | $-0.44 | $600,000 | 1 / 1 |
| 2026-11-02 | $-0.44 | $600,000 | 1 / 1 |
| 2026-11-03 | $-0.44 | $600,000 | 1 / 1 |
| 2026-11-04 | $-0.44 | $600,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 1 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.